Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.36 |
| ▸ | LOX | P28300 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 3/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | GPR3 | P46089 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.35 |
| ▸ | KIF11 | P52732 | 2/20 | 0.35 |
| ▸ | CETP | P11597 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24051598 | 0.90 | GRIN2B (0.42) | MAOBGRIN2B | |
| SCHEMBL16234319 | 0.88 | FFAR4 (0.39) | HTR2CLOXL2MAOBGPR3CETP | |
| SCHEMBL24051776 | 0.87 | MAPT (0.55) | HTR2CST14LOXL2LOXMAOB | |
| SCHEMBL24051492 | 0.87 | L3MBTL1 (0.41) | HTR2CMAOBAOC3CHRM2CHRM1 | |
| SCHEMBL4550729 | 0.86 | GRIN2B (0.46) | HTR2CMAOBAOC3GPR3GRIN2B | |
| SCHEMBL22089768 | 0.86 | IDO1 (0.38) | HTR2CMAOBAOC3GPR3GRIN2B | |
| SCHEMBL8254280 | 0.86 | GRIN2B (0.47) | HTR2CMAOBAOC3GRIN2B | |
| SCHEMBL22090010 | 0.86 | GRIN2B (0.41) | HTR2CST14GRIN2BCETPPRMT6 | |
| Hydrochloric Acid SCHEMBL18741162 | 0.85 | GRIN2B (0.46) | HTR2CMAOBAOC3GRIN2B | |
| SCHEMBL22102110 | 0.83 | EPHX2 (0.38) | HTR2CMAOBGRIN2BKIF11CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| EP-1351962-B1 | THIENOPYRIMIDINE | MERCK PATENT GMBH (DE) | 2005-03-16 | — | — | EP | disclosed |
| US-6780867-B2 | THEY EXHIBIT SPECIFIC INHIBITION OF CGMP PHOSPHODIESTERASE (PDE V) | MERCK PATENT GMBH (DE) | 2004-08-24 | — | — | US | disclosed |
| EP-1351962-A2 | THIENOPYRIMIDINE | MERCK PATENT GmbH (DE) | 2003-10-15 | — | — | EP | disclosed |
| US-20030187260-A1 | Thienopyrimidines | MERCK PATENT GMBH (DE) | 2003-10-02 | — | — | US | disclosed |
| WO-2002018389-A2 | THIENOPYRIMIDINE | MERCK PATENT GMBH (DE) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187260-A1 | Thienopyrimidines | TYMP, DPYD, IMPDH1 | HTR2C 1074/4885ST14 4367/4885LOXL2 4179/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | HTR2C 2157/4885ST14 4406/4885LOXL2 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.